The Seven Stones

EGFR and c-Met core signaling network

Research highlight by Jeongah Yoon and Thomas S. Deisboeck, Massachusetts General Hospital, Charlestown, MA Targeting receptor tyrosine kinases (RTKs) is currently thought to be a promising anti-cancer strategy (Baselga, 2006). However, clinical trials with RTK inhibitors demonstrated that some solid tumors are sensitive to these drugs while others are not. For instance, only a subset of non small cell lung cancer (NSCLC) tumors with EGFR-activating mutations seems to respond to EGFR inhibitors (Lynch et al, 2004). The recent study by Guo et al (2008) aims to shed more light on the causes for such selective drug sensitivity by investigating the 


Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.